{"entity":{"type":"insider","cik":"0001730615","url":"/insider/0001730615","json_url":"/insider/0001730615.json","name":"Violin Jonathan","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":11,"n_filings":7,"first":"2022-02-03","last":"2023-02-07","span_basis":"filed_date"},"name_variants":[{"name":"Violin Jonathan","source":"filing","n_filings":7,"first_seen":"2022-02-03","last_seen":"2023-02-07"}],"transactions":[{"id":9205326,"accession":"0000899243-23-004233","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-23-004233","line_url":"/filing/0000899243-23-004233#line-1","is_derivative":false,"issuer_cik":"0001730615","issuer_name":"Viridian Therapeutics, Inc.\\DE","issuer_ticker":"VRDN","issuer_name_source":null,"issuer_url":"/issuer/0001730615","owner_cik":"0001730615","owner_name":"Violin Jonathan","owner_display_name":"Violin Jonathan","owner_url":"/insider/0001730615","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":50000.0,"shares_display":"50,000","price_per_share":36.8,"price_display":"36.80","price_state":"stated","total_value":1840000.0,"total_display":"1,840,000.00","total_whole":"1,840,000","shares_owned_after":480905.0,"shares_owned_after_display":"480,905","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-02-02","filed_date":"2023-02-07","scope":"insider"},{"id":7834002,"accession":"0000899243-23-003921","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-23-003921","line_url":"/filing/0000899243-23-003921#line-1","is_derivative":false,"issuer_cik":"0001590750","issuer_name":"Viridian Therapeutics, Inc.\\DE","issuer_ticker":"VRDN","issuer_name_source":null,"issuer_url":"/issuer/0001590750","owner_cik":"0001730615","owner_name":"Violin Jonathan","owner_display_name":"Violin Jonathan","owner_url":"/insider/0001730615","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":50000.0,"shares_display":"50,000","price_per_share":36.8,"price_display":"36.80","price_state":"stated","total_value":1840000.0,"total_display":"1,840,000.00","total_whole":"1,840,000","shares_owned_after":430905.0,"shares_owned_after_display":"430,905","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-02-02","filed_date":"2023-02-03","scope":"insider"},{"id":6386116,"accession":"0000899243-22-020717","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-22-020717","line_url":"/filing/0000899243-22-020717#line-1","is_derivative":false,"issuer_cik":"0001590750","issuer_name":"Viridian Therapeutics, Inc.\\DE","issuer_ticker":"VRDN","issuer_name_source":null,"issuer_url":"/issuer/0001590750","owner_cik":"0001730615","owner_name":"Violin Jonathan","owner_display_name":"Violin Jonathan","owner_url":"/insider/0001730615","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":30000.0,"shares_display":"30,000","price_per_share":12.2,"price_display":"12.20","price_state":"stated","total_value":366000.0,"total_display":"366,000.00","total_whole":"366,000","shares_owned_after":480905.0,"shares_owned_after_display":"480,905","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-06-01","filed_date":"2022-06-02","scope":"insider"},{"id":6235608,"accession":"0000899243-22-016657","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-22-016657","line_url":"/filing/0000899243-22-016657#line-1","is_derivative":false,"issuer_cik":"0001590750","issuer_name":"Viridian Therapeutics, Inc.\\DE","issuer_ticker":"VRDN","issuer_name_source":null,"issuer_url":"/issuer/0001590750","owner_cik":"0001730615","owner_name":"Violin Jonathan","owner_display_name":"Violin Jonathan","owner_url":"/insider/0001730615","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":30000.0,"shares_display":"30,000","price_per_share":13.04,"price_display":"13.04","price_state":"stated","total_value":391200.0,"total_display":"391,200.00","total_whole":"391,200","shares_owned_after":510905.0,"shares_owned_after_display":"510,905","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-05-02","filed_date":"2022-05-04","scope":"insider"},{"id":6263742,"accession":"0000899243-22-013858","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-22-013858","line_url":"/filing/0000899243-22-013858#line-2","is_derivative":false,"issuer_cik":"0001590750","issuer_name":"Viridian Therapeutics, Inc.\\DE","issuer_ticker":"VRDN","issuer_name_source":null,"issuer_url":"/issuer/0001590750","owner_cik":"0001730615","owner_name":"Violin Jonathan","owner_display_name":"Violin Jonathan","owner_url":"/insider/0001730615","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3600.0,"shares_display":"3,600","price_per_share":18.93,"price_display":"18.93","price_state":"stated","total_value":68148.0,"total_display":"68,148.00","total_whole":"68,148","shares_owned_after":540905.0,"shares_owned_after_display":"540,905","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-04-04","filed_date":"2022-04-05","scope":"insider"},{"id":6263739,"accession":"0000899243-22-013858","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-22-013858","line_url":"/filing/0000899243-22-013858#line-1","is_derivative":false,"issuer_cik":"0001590750","issuer_name":"Viridian Therapeutics, Inc.\\DE","issuer_ticker":"VRDN","issuer_name_source":null,"issuer_url":"/issuer/0001590750","owner_cik":"0001730615","owner_name":"Violin Jonathan","owner_display_name":"Violin Jonathan","owner_url":"/insider/0001730615","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":26400.0,"shares_display":"26,400","price_per_share":18.92,"price_display":"18.92","price_state":"stated","total_value":499488.0,"total_display":"499,488.00","total_whole":"499,488","shares_owned_after":544505.0,"shares_owned_after_display":"544,505","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-04-01","filed_date":"2022-04-05","scope":"insider"},{"id":6502156,"accession":"0000899243-22-009096","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-22-009096","line_url":"/filing/0000899243-22-009096#line-2","is_derivative":false,"issuer_cik":"0001590750","issuer_name":"Viridian Therapeutics, Inc.\\DE","issuer_ticker":"VRDN","issuer_name_source":null,"issuer_url":"/issuer/0001590750","owner_cik":"0001730615","owner_name":"Violin Jonathan","owner_display_name":"Violin Jonathan","owner_url":"/insider/0001730615","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":11106.0,"shares_display":"11,106","price_per_share":17.36,"price_display":"17.36","price_state":"stated","total_value":192800.16,"total_display":"192,800.16","total_whole":"192,800","shares_owned_after":570905.0,"shares_owned_after_display":"570,905","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-03-02","filed_date":"2022-03-03","scope":"insider"},{"id":6502154,"accession":"0000899243-22-009096","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-22-009096","line_url":"/filing/0000899243-22-009096#line-1","is_derivative":false,"issuer_cik":"0001590750","issuer_name":"Viridian Therapeutics, Inc.\\DE","issuer_ticker":"VRDN","issuer_name_source":null,"issuer_url":"/issuer/0001590750","owner_cik":"0001730615","owner_name":"Violin Jonathan","owner_display_name":"Violin Jonathan","owner_url":"/insider/0001730615","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":18894.0,"shares_display":"18,894","price_per_share":17.82,"price_display":"17.82","price_state":"stated","total_value":336691.08,"total_display":"336,691.08","total_whole":"336,691","shares_owned_after":582011.0,"shares_owned_after_display":"582,011","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-03-01","filed_date":"2022-03-03","scope":"insider"},{"id":6385156,"accession":"0000899243-22-004665","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000899243-22-004665","line_url":"/filing/0000899243-22-004665#line-3","is_derivative":false,"issuer_cik":"0001590750","issuer_name":"Viridian Therapeutics, Inc.\\DE","issuer_ticker":"VRDN","issuer_name_source":null,"issuer_url":"/issuer/0001590750","owner_cik":"0001730615","owner_name":"Violin Jonathan","owner_display_name":"Violin Jonathan","owner_url":"/insider/0001730615","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":909.0,"shares_display":"909","price_per_share":19.16,"price_display":"19.16","price_state":"stated","total_value":17416.44,"total_display":"17,416.44","total_whole":"17,416","shares_owned_after":600905.0,"shares_owned_after_display":"600,905","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-02-03","filed_date":"2022-02-03","scope":"insider"},{"id":6385153,"accession":"0000899243-22-004665","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-22-004665","line_url":"/filing/0000899243-22-004665#line-2","is_derivative":false,"issuer_cik":"0001590750","issuer_name":"Viridian Therapeutics, Inc.\\DE","issuer_ticker":"VRDN","issuer_name_source":null,"issuer_url":"/issuer/0001590750","owner_cik":"0001730615","owner_name":"Violin Jonathan","owner_display_name":"Violin Jonathan","owner_url":"/insider/0001730615","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":12340.0,"shares_display":"12,340","price_per_share":18.47,"price_display":"18.47","price_state":"stated","total_value":227919.8,"total_display":"227,919.80","total_whole":"227,920","shares_owned_after":601814.0,"shares_owned_after_display":"601,814","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-02-02","filed_date":"2022-02-03","scope":"insider"},{"id":6385148,"accession":"0000899243-22-004665","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-22-004665","line_url":"/filing/0000899243-22-004665#line-1","is_derivative":false,"issuer_cik":"0001590750","issuer_name":"Viridian Therapeutics, Inc.\\DE","issuer_ticker":"VRDN","issuer_name_source":null,"issuer_url":"/issuer/0001590750","owner_cik":"0001730615","owner_name":"Violin Jonathan","owner_display_name":"Violin Jonathan","owner_url":"/insider/0001730615","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":16751.0,"shares_display":"16,751","price_per_share":19.55,"price_display":"19.55","price_state":"stated","total_value":327482.05,"total_display":"327,482.05","total_whole":"327,482","shares_owned_after":614154.0,"shares_owned_after_display":"614,154","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-02-01","filed_date":"2022-02-03","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":11,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":11,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":11},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001590750","name":"Viridian Therapeutics, Inc.\\DE","url":"/issuer/0001590750","role":"Director, Officer (Chief Executive Officer)","n_filings":7,"first_seen":"2022-02-03","last_seen":"2023-02-07"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001730615","retrieved_at":"2026-08-22T09:37:13+00:00","coverage":{"filings":1505395,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}